Objective-Endothelial cell (EC) migration, essential for reestablishing arterial integrity after vascular injury, is inhibited by oxidized LDL (oxLDL) and lysophosphatidylcholine (lysoPC) that are present in the arterial wall. We tested the hypothesis that a mechanism responsible for lysoPC-induced inhibition is increased intracellular free calcium concentration ([Ca 2ϩ ] i ).
variety of normal and pathological processes, including angiogenesis, tumor metastasis, and restoration of endothelial integrity after arterial injury. EC movement is altered by many factors, including oxidatively modified lipids and lipoproteins. Previous studies have shown that oxidized LDL (oxLDL), but not unmodified LDL, suppresses EC migration in vitro. 1, 2 In addition, lysophosphatidylcholine (lysoPC), a major lipid constituent formed during oxidation of LDL, inhibits EC movement in vitro. 1, 3 LysoPC is abundant in the plasma 4 and accumulates in atherosclerotic lesions. 5 Thus, lysoPC might adversely affect restoration of endothelial integrity after angioplasty of an atherosclerotic vessel. Despite the potential clinical importance of suppressed EC migration, the mechanism(s) by which oxLDL or lysoPC inhibits EC movement is poorly understood.
LysoPC integrates into cell membranes and can cause structural and functional alterations. Inhibition of EC migration by lysophospholipids is related to chain length and head-group size, 3 suggesting that spatial disruption of lipid packing in the membrane affects membrane function and alters membrane fluidity. 6 In addition, lysoPC can alter ion channels 7 and increase the intracellular free calcium concentration ([Ca 2ϩ ] i ) in ECs. 8 Several studies have shown that changes in [Ca 2ϩ ] i are important in EC migration. An increase in [Ca 2ϩ ] i is required to initiate movement after an EC monolayer is wounded. 9 On the other hand, [Ca 2ϩ ] i is lower in migrating ECs, especially at the leading edge, 10 suggesting that precise regulation of [Ca 2ϩ ] i is essential for normal migration. Therefore, the lysoPC-induced increase in [Ca 2ϩ ] i may contribute to the inhibition of migration by disrupting the time-or site-specific changes in [Ca 2ϩ ] i required for cell movement.
Calcium influx activates a number of intracellular proteases and signaling pathways. One such group of proteases is the calpains. Calpains are intracellular, nonlysosomal, cysteine proteases that are activated by increased [Ca 2ϩ ] i . Substrates for calpains include a variety of cytoskeletal proteins, tyrosine kinases, and phosphatases. 11 Activated calpain is required for disruption of integrin-cytoskeletal linkages at the rear of the cell while lamellipodia protrusions and new adhesions and cytoskeletal attachments are forming at the leading edge of the cell. 12, 13 In the current study, we explore the causal relation between lysoPC-induced increases in [Ca 2ϩ ] i , activation of calpain and inhibition of EC migration. We demonstrate that lysoPC, at concentrations that inhibit migration, increases [Ca 2ϩ ] i . The increase in [Ca 2ϩ ] i can be blunted by calcium chelators and channel blockers, and these agents also preserve EC migration. Calpain activation is induced by lysoPC, and calpain inhibitors partially preserve EC migration in the presence of lysoPC, suggesting that the mechanism by which lysoPC inhibits EC migration involves increased [Ca 2ϩ ] i and calpain activation.
Methods

Materials
Fura 2-AM, A23187, BAPTA/AM, EGTA/AM, calpeptin, MDL28170, and calpastatin peptide were purchased from Calbiochem. 1-Palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine (ly-soPC) was purchased from Avanti Polar Lipids. Monoclonal antibodies against calpain and calpastatin were purchased from Biomol (Plymouth Meeting, Pa). Monoclonal antibodies to talin, filamin, and actin were obtained from Chemicon (Temecula, Calif). Other chemicals were purchased from Sigma.
EC Culture and Cell Migration Assay
Bovine aortic ECs were isolated from fresh adult bovine aortas by gentle scraping after collagenase exposure. Cells between passages 4 and 10 were grown in Dulbecco's modified Eagle's medium (DMEM) and Ham's F12 nutrient mixture (1:1, vol/vol) containing 10% fetal calf serum (Hyclone Laboratories). EC migration was measured by the razor wound assay as previously described. 1 In brief, 12-well tissue-culture plates containing a confluent monolayer of ECs were incubated overnight in serum-free DMEM containing 0.1% gelatin. A sterile razor blade was gently pressed into the plastic to mark a start line and then swept laterally to remove cells on one side of that line. ECs were allowed to migrate for 24 hours, then fixed, and stained with a modified Wright-Giemsa stain. An observer, blinded to the experimental conditions, measured cell migration by capturing images of 3 fields corresponding to a starting line length of 1.34 mm with the use of a digital CCD camera mounted on a phase-contrast microscope. Results of each experiment represent data from triplicate wells, expressed as meanϮSD of the number of cells crossing 1.34 mm of the starting line. The effect of various compounds on EC migration was expressed as a percentage of migration in control wells.
Measurement of [Ca 2؉ ] i
The [Ca 2ϩ ] i was estimated by using the Ca 2ϩ -binding fluorophore fura-2 as previously described. 14 In brief, ECs were cultured in 35-mm dishes designed for fluorescence microscopy (Bioptechs) and made quiescent overnight in serum-free DMEM. Cells were loaded with fura 2-AM (1 mol/L) for 30 minutes and then washed with Krebs-Ringer (KR) buffer (125 mmol/L NaCl, 5 mmol/L KCl, 1.2 mmol/L MgSO 4 , 11 mmol/L glucose, 2.5 mmol/L CaCl 2 , and 25 mmol/L HEPES at pH 7.4) to remove excess fura-2. Fluorescence of a cluster of 6 to 8 cells located inside the light path was continuously monitored with an Olympus 1X-70 inverted fluorescence microscope cycling dual-excitation wavelengths of 340 and 380 nm and an emission wavelength of 510 nm (Photon Technology International). The ratio of fura-2 fluorescence intensity at the 2 excitation wavelengths (340/380 ratio) was used to determine the relative change in [Ca 2ϩ ] i . 15
Immunoblot Analysis for Calpain Activation
Calpain activity was estimated by monitoring calpain autolysis and the in vivo degradation of 2 of its cytoskeletal protein substrates, talin and filamin. ECs were cultured overnight in serum-free DMEM with 0.1% gelatin before addition of the compound(s) to be tested. At the indicated times, cells were solubilized in cold lysis buffer containing protease inhibitors [20 mmol/L Tris-HCl, pH 7.2, with 150 mmol/L NaCl, 1% Triton X-100, 0.1% SDS, 1 mmol/L EDTA, 10 g/mL aprotinin, and 0.01 mmol/L 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride). Proteins were separated on a 4% to 12% gradient SDS-polyacrylamide electrophoresis gel, transferred to a polyvinylidene difluoride membrane, and probed with specific antibodies.
Results
LysoPC-Induced Increase in [Ca 2؉ ] i and Inhibition of EC Migration
In view of evidence that lysoPC increases [Ca 2ϩ ] i , 8 and that [Ca 2ϩ ] i is important in migration, 9, 10 our initial objective was to establish the correlation between a lysoPC-induced rise in [Ca 2ϩ ] i and inhibition of EC migration. LysoPC (12.5 mol/L) induced a significant increase in [Ca 2ϩ ] i , as determined by the calcium-sensitive fluorophore fura-2. Typically, the [Ca 2ϩ ] i rose Ϸ10 minutes after addition of lysoPC, the elevation was sustained, and the [Ca 2ϩ ] i returned toward baseline after 2 hours. The increase in [Ca 2ϩ ] i could be reversed by removing the lysoPC. After [Ca 2ϩ ] i returned to baseline, repeated addition of lysoPC induced an identical increase in [Ca 2ϩ ] i (Figure 1 ). The effect of lysoPC on both the [Ca 2ϩ ] i increase and EC migration was dependent on the concentration of lysoPC ( Figure 2 ). Maximum effect was noted at Ϸ12.5 mol/L lysoPC. The same concentration of lysoPC inhibited EC migration during 24 hours to 35% of control. LysoPC (12.5 mol/L) was not cytotoxic and was below the reported critical micellar concentration of 40 to 50 mol/L. 3, 16 Migration was restored by removal of lysoPC. These results supported the hypothesis that the lysoPC-induced increase in [Ca 2ϩ ] i contributed to inhibition of EC migration.
LysoPC-Induced Rise in [Ca 2؉ ] i Through Nonvoltage-Sensitive Channels
LysoPC can intercalate into the cell membrane and modulate ion channel function, 7 and this may induce the increase in [Ca 2ϩ ] i . LysoPC did not cause an elevation in [Ca 2ϩ ] i when ECs were incubated in calcium-free KR buffer (data not shown), confirming that the source of Ca 2ϩ was extracellular. The pathway of calcium entry was assessed by using nonvoltage-gated and voltage-gated channel blockers. LaCl 3 (250 mol/L), a non-voltage-sensitive channel blocker, reduced the magnitude of the increase in [Ca 2ϩ ] i observed after lysoPC treatment (Figure 3 ). The diminished rise in [Ca 2ϩ ] i was accompanied by partial preservation of EC migration. LaCl 3 maintained EC migration in the presence of lysoPC at 68% of control level (Figure 3 ). Similar results were observed with gadolinium chloride, another nonvoltage-sensitive channel blocker (data not shown). Bovine ECs apparently lack voltage-gated calcium channels, 17 so, as expected, the voltage-sensitive channel blockers nifedipine and nitrendipine did not alter the rise in [Ca 2ϩ ] i induced by lysoPC (data not shown). Our data suggested that after lysoPC treatment, calcium entered ECs through nonvoltage-gated channels and perhaps through additional channels not affected by nonvoltage-or voltage-sensitive channel blockers.
Calcium Chelators Preserved EC Migration in the Presence of LysoPC
The importance of calcium in lysoPC-induced inhibition of EC migration was further assessed by blocking the rise in [Ca 2ϩ ] i by loading cells with intracellular calcium chelators. ECs that were loaded with BAPTA/AM (25 mol/L) for 30 minutes and then treated with lysoPC had a blunted rise in [Ca 2ϩ ] i (Figure 4 ). At the same time, BAPTA/AM loading preserved EC migration to 67% of control levels (Figure 4 ). Similar to the observation with the channel blockers, BAPTA/AM did not completely prevent the increase in [Ca 2ϩ ] i , and this was correlated with incomplete preservation of EC migration in the presence of lysoPC. Similar effects on [Ca 2ϩ ] i and migration were observed with EGTA/AM (data not shown). The observation that calcium channel blockers and calcium chelators blunted the increase in [Ca 2ϩ ] i and partially preserved migration supported the hypothesis that the lysoPC-induced rise in [Ca 2ϩ ] i inhibited EC migration.
Calcium Ionophore Inhibited EC Migration
The role of calcium in the inhibition of EC migration was studied with an alternative mechanism to increase [Ca 2ϩ ] i . A23187, a calcium ionophore, increased [Ca 2ϩ ] i in a pattern closely resembling that of lysoPC, with a rapid and sustained elevation in [Ca 2ϩ ] i (data not shown). A23187 (100 nmol/L) decreased EC migration to 22% of control levels (nϭ8, PϽ0.0001). As was observed with lysoPC, the presence of an intracellular calcium chelator, BAPTA/AM, partially preserved migration of A23187-treated ECs, restoring migration to 44% of control level, significantly improved compared with A23187 alone (Pϭ0.0005). LysoPC and A23187 were strikingly similar in their abilities to induce a sustained increase in [Ca 2ϩ ] i and inhibit EC migration.
A prolonged increase in [Ca 2ϩ ] i inhibited EC migration, but a transient rise in calcium did not affect cell movement in the razor scrape assay. Bradykinin (100 nmol/L), a substance that induces a rapid release of calcium from intracellular stores, increased [Ca 2ϩ ] i to a similar level as lysoPC, but the increase lasted for only 2 minutes (data not shown). Bradykinin had no effect on EC migration. The number of ECs migrating across 1.34 mm of the starting line in control wells was 440Ϯ113 compared with 422Ϯ121, 424Ϯ115, and 419Ϯ117 in 100 nmol/L, 200 nmol/L, and 500 nmol/L bradykinin, respectively (PՆ0.5). The inability of a transient rise in [Ca 2ϩ ] i to alter migration suggested that a prolonged elevation of [Ca 2ϩ ] i is essential for inhibition of EC migration by lysoPC.
LysoPC Increased Activation of Calpain in ECs
Changes in cell morphology noted during EC migration assays paralleled the time course of [Ca 2ϩ ] i changes. One hour after initiation of the migration assay, control ECs were elongated and beginning to extend lamellipodia. LysoPCtreated ECs, on the other hand, became rounded and remained so for 2.5 hours. Then ECs began to resume a more normal shape and by 4 hours had regained a flattened, spread appearance (data not shown). This observation prompted investigation into pathways causing cytoskeletal alterations.
Increased [Ca 2ϩ ] i can induce calpain activation with autolysis of the calpain molecule and increased proteolytic activity. Calpain autolysis during EC incubation with lysoPC was assessed by immunoblot analysis. A marked increase in the 76-kDa cleavage product, relative to the intact 80-kDa protein, was detected after 1 hour of exposure to lysoPC and persisted for at least 4 hours (data not shown). The intensity of the 76-kDa band slowly declined but was still increased at 24 hours compared with baseline. The level of calpastatin, the natural inhibitor of calpain, was also determined by immunoblot analysis, and no changes in calpastatin levels were detected during intervals ranging from 1 to 24 hours (data not shown). This suggested that calpain activity was increased.
To confirm that calpain proteolytic activity was increased in response to lysoPC, the appearance of talin and filamin degradation products in cell lysates was assessed by immunoblot analysis. LysoPC treatment of ECs resulted in increased calpain proteolytic activity within 1 hour, as indicated by a rise in the 47-kDa breakdown product of talin, and the cleavage product was elevated for at least 4 hours ( Figure 5) . The time course paralleled that in the immunoblot analysis of calpain autolysis. Similar results were observed for filamin degradation after lysoPC treatment of ECs (data not shown). Inhibitors of calpain, including calpastatin (1 mol/L, Figure   6 ), calpeptin (1 mol/L), and MDL28170 (1 mol/L), inhibited the lysoPC-induced talin degradation. Interestingly, intracellular calcium chelators and the nonvoltage-sensitive channel blockers, BAPTA/AM and LaCl 3 , also prevented activation of calpain (data not shown), suggesting that the lysoPC-induced rise in [Ca 2ϩ ] i caused calpain activation.
Calpain Inhibitors Preserved Migration in LysoPC-Treated ECs
The role of calpain activation in the lysoPC-induced inhibition of EC migration was also assessed. Calpastatin peptide, at a concentration that prevented the degradation of talin, partially preserved EC migration in the presence of lysoPC ( Figure 6 ). Similar results were found with other calpain inhibitors, including calpeptin (1 mol/L) and MDL28170 (1 mol/L). Each compound restored movement to a similar extent, with calpeptin, MDL28170, and calpastatin preserving migration at 56%, 61%, and 62%, respectively, of control levels. These observations suggest that calpain activation was a mechanism by which lysoPC inhibits EC migration.
Discussion
Cell migration involves multiple simultaneous processes. These include focal adhesion formation and insertion of membrane mass at the leading edge of the cell, intracellular force generation by actin polymerization, and focal adhesion disassembly and retrieval of membrane mass at the rear of the cell. 18 These dynamic processes require complex intracellular signaling events including calcium influx. OxLDL and one of its major lipid components, lysoPC, inhibited EC migration, 1,3 and both oxLDL and lysoPC increased intracellular [Ca 2ϩ ] i . 19, 20 This study focused on the causal relation between lysoPC-mediated changes in [Ca 2ϩ ] i and the inhibition of EC migration.
The rise in [Ca 2ϩ ] i after addition of lysoPC requires influx of Ca 2ϩ from the extracellular space through nonselective calcium channels. Inoue et al 8 suggest that lysoPC causes a biphasic increase in [Ca 2ϩ ] i , with a rapid initial increase caused by release of calcium from intracellular stores followed by a sustained elevation in [Ca 2ϩ ] i due to influx of extracellular calcium. In our experiments, no early spike in [Ca 2ϩ ] i was seen after addition of lysoPC. One explanation for the discrepancy might be contamination of some commercial preparations of lysoPC with phospholipids that have plateletactivating factor (PAF) activity, 21 and PAF causes a rapid increase in [Ca 2ϩ ] i in ECs. 22 PAF-like activity does not appear to be responsible for our findings, because PAF receptor antagonists and pretreatment of the lysoPC preparations with phospholipase A 2 , which would remove sn-2 residues from PAF but not affect the structure of lysoPC, did not alter the effect on EC migration (data not shown).
Calcium flux plays a critical role in migration, and highly regulated [Ca 2ϩ ] i transients must occur for normal migration. A spike in [Ca 2ϩ ] i is required to initiate EC migration, 9 and agents that inhibit calcium influx delay healing. 23 On the other hand, a sustained increase of [Ca 2ϩ ] i by lysoPC, calcium ionophore, or thapsigargin in the presence of extracellular Ca 2ϩ (data not shown) inhibits migration. Thus, both inhibition and excessive stimulation of calcium influx can suppress migration, perhaps by disturbing highly localized [Ca 2ϩ ] i transients that regulate cell attachment to the substratum at the leading edge and de-adhesion at the rear of the cell.
Precise site-specific regulation of calpain activation is also required for normal cell migration. Calpain is selectively activated at sites of integrin signaling complexes and can cleave proteins in these complexes, including integrin subunits and cytoskeletal proteins. 24 Interruption of calpain activation can impair cell movement, as shown in calpaindeficient mouse fibroblasts and Chinese hamster ovary cells. 12, 25 Overexpression of calpastatin, the endogenous calpain inhibitor, 13 or addition of exogenous calpain inhibitors 12 impedes cell spreading and migration. These reports suggest that calpain is required for moving cells to detach from their substrate at their trailing edge and extend lamellipodia at their leading edge. On the other hand, our studies show that a generalized, sustained activation of calpain also inhibits EC migration. Transfected ECs that overexpress -calpain have an overspread appearance, with increased stress fibers and focal adhesions. 26 In our preliminary studies, these cells have very limited capacity to migrate (data not shown), and 5 mol/L lysoPC disrupts focal adhesions, causing cells to lift from the substratum. These studies suggest that generalized inhibition or activation of calpain disrupts the time-and site-specific regulation required for normal cell migration and results in inhibition of movement.
Our studies show that calpain inhibitors (calpeptin, MDL28170, and calpastatin) partially preserve EC migration in lysoPC, although calpain inhibitors are reported to block cell spreading. This apparent contradiction is explained by our use of very low concentrations of these inhibitors (1 mol/L), selected on the basis of preliminary studies that showed no effect on basal EC migration but prevention of lysoPC-induced calpain proteolytic activity as measured by talin breakdown. These concentrations are far below the 50 to 275 mol/L concentrations reported to inhibit cell spreading. 13, 26 Most calpain inhibitors are not specific and can block cysteine and serine proteases; 27 and calpeptin can inhibit protein tyrosine phosphatases. 28 Calpastatin, however, is a specific inhibitor of calpain and does not inhibit other cysteine or serine proteases in vitro. 29 The ability of calpastatin to preserve migration of lysoPC-treated ECs supports the hypothesis that diffuse, sustained calpain activation is a mechanism by which lysoPC impairs movement.
Our results suggest that lysoPC inhibits migration in part by inducing an increase in [Ca 2ϩ ] i that upregulates calpain activity. Calpain, in turn, can cleave cytoskeletal proteins, alter focal adhesion plaques, and activate tyrosine kinases and phosphatases. 11, 24 Blunting the increase in [Ca 2ϩ ] i or inhibiting calpain activity partially preserves EC migration. The morphological changes of ECs after addition of lysoPC suggests that calpain impairs migration by excessive breakdown of cytoskeletal proteins. Although lysoPC also inhibits human EC migration in vitro (data not shown), assignment of clinical significance to these findings is premature. Further in vitro and in vivo studies are needed to better understand the mechanisms by which lipid oxidation products inhibit cell movement and to develop therapeutic agents to promote migration and restore endothelial integrity after angioplasty.
